So, Avexa's drug is "one of the most exciting unpartnered HIV...

So, Avexa's drug is "one of the most exciting unpartnered HIV drugs in development"?

How many are there? Hundreds? (Of unpartnered HIV drugs.) And, not to put a dampener on things, but saying "one of" means that there is no standout candidate. Which is fine, although somewhat of a cop-out.

I'm still a buyer at these discounted levels, but you have to wonder about analysts which make such double-edged statements. At this stage of the game, Avexa's only competitor is, surprisingly, itself.